The European Vasculitis Society 2016 Meeting Report
(2017) In Kidney International Reports 2(6). p.1018-1031- Abstract
The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several... (More)
The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.
(Less)
- author
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- keywords
- ANCA, renal outcome, therapy, vasculitis
- in
- Kidney International Reports
- volume
- 2
- issue
- 6
- pages
- 14 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85040727203
- pmid:29634043
- ISSN
- 2468-0249
- DOI
- 10.1016/j.ekir.2017.09.008
- language
- English
- LU publication?
- yes
- additional info
- Meeting Report
- id
- 8bc8548a-633c-4edb-bd89-f40a961e81cd
- date added to LUP
- 2018-02-05 16:20:42
- date last changed
- 2024-06-24 09:31:15
@article{8bc8548a-633c-4edb-bd89-f40a961e81cd,
abstract = {{<p>The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.</p>}},
author = {{Bajema, Ingeborg M. and Bruijn, Jan A. and Casian, Alina and Cid, Maria C. and Csernok, Elena and van Daalen, Emma and Harper, Lorraine and Hauser, Thomas and Little, Mark A. and Luqmani, Raashid A. and Mahr, Alfred and Ponte, Cristina and Salama, Alan and Segelmark, Mårten and Suzuki, Kazuo and Sznajd, Jan and Teng, Y. K.Onno and Vaglio, Augusto and Westman, Kerstin and Jayne, David}},
issn = {{2468-0249}},
keywords = {{ANCA; renal outcome; therapy; vasculitis}},
language = {{eng}},
number = {{6}},
pages = {{1018--1031}},
publisher = {{Elsevier}},
series = {{Kidney International Reports}},
title = {{The European Vasculitis Society 2016 Meeting Report}},
url = {{http://dx.doi.org/10.1016/j.ekir.2017.09.008}},
doi = {{10.1016/j.ekir.2017.09.008}},
volume = {{2}},
year = {{2017}},
}